Clinical Trial Update: An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients [Phase 2]

View source ↗

Summary

Phase 2 exploratory study evaluating OCZ103-OS in combination with standard of care in Stage IV non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OCZ103-OS

Snippet

Sponsor: Oncozyme Pharma Inc. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED